EUVIMEDEUVIMED entdecken
CrossrefInfokarte

IFN-Based and IFN-Free Direct-Acting Antiviral Drug Treatments for Acquired Hepatitis C Virus in Post-Transplant Recipients

Tomomi Kogiso, Mutsuki Kobayashi, Kuniko Yamamoto, Yuichi Ikarashi, Kazuhisa Kodama, Makiko Taniai, Nobuyuki Torii, Kazunari Tanabe, Hideki Ishida, Shohei Fuchinoue, Hiroto Egawa, Masakazu Yamamoto, Etsuko Hashimoto, Katsutoshi Tokushige

OBM Hepatology and Gastroenterology · 2017

DOI: 10.21926/obm.hg.1702003 ↗
AbstractBibliografische Angaben

Abstract

Background: Hepatitis C virus (HCV) infection frequently occurs in recipients of liver or kidney transplants (LT/KT). Interferon (IFN)-based therapies are used to treat HCV, but their efficacy is low. Methods: We report 24 patients who received HCV therapy after LT/KT. Design, Setting, and Participants-Twelve LT and 12 KT recipients (median age, 59 years; 15 males; 21 serological type 1) were enrolled, of whom eight (six with LT) were treated with IFN-based therapy. Twelve received direct-acting antiviral drugs [DAAs; daclatasvir (DCV)/asunaprevir (ASV) therapy] for 24 weeks, seven received sofosbuvir (SOF)/ledipasvir (LDV) for 12 weeks, and one received SOF/ribavirin for 12 weeks. Results: In two LT patients, HCV resolved spontaneously after LT. Six patients received IFN, of whom one achieved a sustained virological response for 24 or more weeks (SVR) (16.7%), three cases stopped treatment due to side effects (anemia and infection), and two cases relapsed. Five received DCV/ASV, and four received SOF-based DAA, including those with IFN failure. All patients completed treatment with a SVR. Two KT cases were treated with IFN; one was successfully treated and one discontinued treatment due to renal rejection. All cases, including the one IFN failure, achieved a SVR after DAA therapy. Two who received DCV/ASV showed a low estimated glomerular filtration rate (eGFR), and three who received SOF/LDV contained the NS5A mutation. HCV treatment by DAAs was successful in all patients. Conclusions: DAAs were highly effective and safe in LT/KT recipients who failed IFN-based therapy and had a low eGFR or the NS5A mutation.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →